Last Updated on October 10, 2024 by The Health Master
Hyderabad: Aurobindo Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for Unit XIV located at Bonangi Village, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District, Andhra Pradesh.
The U.S. regulator conducted an inspection of unit XIV from May 15 to 19, 2023.
“The Unit has now received the Establishment Inspection Report classifying the facility as “Voluntary action indicated” (VAI),’‘ the Hyderabad-based company informed the BSE on Monday.
The exact details of VAI have not been disclosed.
USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad
USFDA issues Form 483 to Lupin with 2 observations: Nagpur
USFDA completes inspection of Granules India in two facilities
USFDA completes inspection at Ajanta Pharma with zero observations: Gujarat
USFDA concludes inspection at Zydus with zero observation
USFDA completes inspection of Dr Reddy’s with zero observation
The Impact of Online Pharmacies on the Conventional Drug Distribution System
Drug Alert Process: Factors to Consider for Drug Regulator
USFDA gives approval for OTC Acetaminophen and Ibuprofen Tablets
Pharma company penalised Rs 45 lakh for pollution
NABL: Awareness on accreditation for Drugs and Pharma Testing Laboratories
USFDA declines to approve this Parkinson’s drug
USFDA gives tentative nod for Dolutegravir tablets for oral suspension
USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad
Drug recall: Dronabinol Capsules, Ziprasidone HCL Capsules recalled due to this reason
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
